[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glnh\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glnh":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":5},"100271815","international-registry-for-patients-with-castleman-disease-100271815",false,"NCT02817997","International Registry for Patients With Castleman Disease","ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment\u002FEffectiveness Research): An International Registry for Patients With Castleman Disease","ACCELERATE","Inclusion Criteria:\n\n* Person of any age\n* Have a reference pathology report suggesting \"Castleman disease\" not limited to cutaneous involvement only that can be uploaded\n* Be able to provide electronic informed consent, as per local regulations\n* Deceased patients may also be enrolled when a reference pathology report suggesting \"Castleman disease\" can be supplied or when the ART is able to locate and upload such a pathology report.\n\nExclusion Criteria:\n\n* Because this registry is designed to provide as wide a picture of routine clinical practice as possible, inclusion criteria are set deliberately wide and there are no exclusion criteria.","ALL",{"count":19,"type":20},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.",[25,26,27,28,29,30,31,32,33],"Castleman Disease","Castleman's Disease","Giant Lymph Node Hyperplasia","Angiofollicular Lymph Hyperplasia","Angiofollicular Lymph Node Hyperplasia","Angiofollicular Lymphoid Hyperplasia","GLNH","Hyperplasia, Giant Lymph Node","Lymph Node Hyperplasia, Giant",[35,36,37,38,39,40,26,28,41,42],"patient registry","ACCELERATE study","CD","MCD","iMCD","Castleman","multicentric Castleman's disease","multicentric Castleman disease","RECRUITING","2026-02-27",{"date":46,"type":47},"2026-03-03","ACTUAL",{"date":49,"type":4},"2016-10",{"date":51,"type":20},"2027-09",{"name":53,"class":54},"University of Pennsylvania","OTHER"]